ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P TSX Capped Composite...
32.47
(
0.28%
)
US Tech 100
15,700.80
(
0.54%
)
S&P 500
4,604.37
(
0.41%
)
US Dollar vs CAD
1.35945
(
0.0%
)
Bitcoin
43,993.96
(
-0.43%
)
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) News

REGN Regeneron Pharmaceuticals Inc

842.0426
-7.14 (-0.84%)
Dec 08 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Regeneron Pharmaceuticals Inc REGN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-7.14 -0.84% 842.0426 19:00:00
Open Price Low Price High Price Close Price Previous Close
844.33 839.55 848.02 840.14 849.18
more quote information »

Recent News

Date Time Source Heading
12/07/202306:00GLOBEUpdated Linvoseltamab Pivotal Data Demonstrated Strong Rates..
12/07/202301:30GLOBERegeneron to Share Progress of Novel Combination Therapies..
12/06/202315:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/05/202315:02EDGAR2Form 144 - Report of proposed sale of securities
12/04/202315:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/30/202315:05GLOBERegeneron to Host Investor Call and Webcast on December 14,..
11/27/202300:30GLOBEDupixent® (dupilumab) Significantly Reduced COPD..
11/16/202310:39DJNRegeneron Currently Down Eight Consecutive Days, On Track..
11/15/202315:05GLOBERegeneron Announces Investor Conference Presentation
11/15/202315:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/15/202310:29DJNRegeneron Pharmaceuticals Currently Down Seven Consecutive..
11/14/202315:02EDGAR2Form 144 - Report of proposed sale of securities
11/13/202308:00GLOBERegeneron Commits $34 Million Over Five Years to Continue to..
11/10/202309:00DJNBayer Gets CHMP Backing for Higher-Dose Eylea in Two Major..
11/08/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/07/202315:45EDGAR2Form 144 - Report of proposed sale of securities
11/03/202306:32IHMARKETNEWSFriday’s Wall Street Highlights: Apple, Bill Holdings,..
11/03/202306:00GLOBERegeneron to Highlight Scientific Advancements Across..
11/02/202315:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/02/202306:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202306:10EDGAR2Form 8-K - Current report
11/02/202305:30GLOBERegeneron Reports Third Quarter 2023 Financial and Operating..
11/01/202315:48EDGAR2Form 144 - Report of proposed sale of securities
11/01/202315:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Data Presentations at..
10/26/202315:00GLOBERegeneron Shares Preliminary Results Showing Gene Therapy..
10/25/202315:05GLOBERegeneron Announces Investor Conference Presentations
10/22/202313:59GLOBEDupixent® (dupilumab) Phase 3 Results Show Sustained..
10/21/202307:48GLOBELibtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates..
10/20/202316:00GLOBERegeneron and Sanofi Provide Update on Dupixent® (dupilumab)..
10/18/202308:30GLOBERegeneron builds on Together for CHANGE™ initiative with..
10/18/202308:00GLOBETogether for CHANGE Genomics and Equity Initiative Launched..
10/17/202315:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/15/202317:05GLOBERegeneron to Showcase Progress from Innovative Oncology..
10/13/202315:02EDGAR2Form 144 - Report of proposed sale of securities
10/13/202310:57DJNRegeneron Pharmaceuticals on Pace for Record High Close --..
10/05/202315:04EDGAR2Form 8-K - Current report
10/05/202308:43GLOBEEYLEA® HD (aflibercept) Injection 8 mg Two-year Results from..
10/03/202315:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/03/202314:49EDGAR2Form 144 - Report of proposed sale of securities
10/03/202306:00GLOBERegeneron and Intellia Announce Expanded Research..
10/02/202315:18EDGAR2Form 144 - Report of proposed sale of securities
9/29/202308:11DJNRegeneron Gets FDA Priority Review of Odronextamab in..
9/29/202307:30GLOBEOdronextamab BLA for Treatment of Relapsed/Refractory..
9/28/202315:05GLOBERegeneron to Report Third Quarter 2023 Financial..
9/27/202315:05EDGAR2Form SC 13D/A - General statement of acquisition of..
9/26/202300:29GLOBEDupixent® (dupilumab) sBLA for Treatment of Eosinophilic..
9/25/202317:12DJNUltragenyx Says the Cholesterol Evkeeza Gets Canadian..
9/25/202316:13GLOBEUltragenyx Launches Evkeeza® (evinacumab for injection) in..
9/25/202307:48EDGAR2Form SC TO-T/A - Tender offer statement by Third Party:..
9/25/202307:34GLOBERegeneron Completes Acquisition of Decibel Therapeutics,..

Your Recent History

NASDAQ
REGN
Regeneron Pharmaceuticals
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com